Anticalins in drug development

BioDrugs

Volumn 19, Issue 5, 2005, Pages 279-288

  Schlehuber, Steffen ^a   Skerra, Arne ^b  

^a Pieris Pharmaceuticals GmbH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBODY; ANTICALIN; ANTICALIN DIGA16; ANTIDOTE; ANTIGEN; BINDING PROTEIN; BL 22; CALICHEAMICIN; CELL SURFACE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIGICAL; DIGOXIN; DIGOXIN ANTIBODY F(AB) FRAGMENT; GEMTUZUMAB OZOGAMICIN; HAPTEN; HYBRID PROTEIN; IMMUNOTOXIN LMB2; IMMUNOTOXIN LMB9; INFLIXIMAB; IPILIMUMAB; LIPOCALIN; OKT 3; PLASMA PROTEIN; RECEPTOR BLOCKING AGENT; RITUXIMAB; TOXIC SUBSTANCE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN BINDING; BINDING AFFINITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG ANALYSIS; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LIGAND BINDING; LIVER TOXICITY; MUTAGENESIS; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TUMOR;

ANIMALS; ANTIBODIES; ANTIDOTES; CARRIER PROTEINS; DRUG DESIGN; HUMANS; LIGANDS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN FOLDING;

EID: 26444478115     PISSN: 11738804     EISSN: 11738804     Source Type: Journal    
DOI: 10.2165/00063030-200519050-00001     Document Type: Review

References (86)

1. Flower DR. The lipocalin protein family: structure and function. Biochem J 1996; 318 (Pt 1): 1-14
2. Skerra A. Lipocalins as a scaffold. Biochim Biophys Acta 2000; 1482 (1-2): 337-50
3. Newcomer ME, Jones TA, Aqvist J, et al. The three-dimensional structure of retinol-binding protein. EMBO J 1984; 3 (7): 1451-4
4. Bishop RE, Weiner JH. 'Outlier' lipocalins more than peripheral. Trends Biochem Sci 1996; 21 (4): 127
5. Flower DR. Multiple molecular recognition properties of the lipocalin protein family. J Mol Recognit 1995; 8 (3): 185-95
6. Cowan S, Newcomer M, Jones T. Crystallographic refinement of human serum retinol binding protein at 2 Å resolution. Proteins 1990; 8 (1): 44-61
7. Bocskei Z, Groom CR, Flower DR, et al. Pheromone binding to two rodent urinary proteins revealed by x-ray crystallography. Nature 1992; 360 (6400): 186-8
8. Bianchet MA, Bains G, Pelosi P, et al. The three-dimensional structure of bovine odorant binding protein and its mechanism of odor recognition. Nat Struct Biol 1996; 3 (11): 934-9
9. Urade Y, Hayaishi O. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta 2000; 1482 (1-2): 259-71
10. Schmid K, Kaufmann H, Isemura S, et al. Structure of α1-acid glycoprotein: the complete amino acid sequence, multiple amino acid substitutions, and homology with the immunoglobulins. Biochemistry 1973; 12 (14): 2711-24
11. Skerra A. Imitating the humoral immune response. Curr Opin Chem Biol 2003; 7 (6): 683-93
12. Goetz DH, Holmes MA, Borregaard N, et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002; 10 (5): 1033-43
13. Holmes MA, Paulsene W, Jide X, et al. Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. Structure (Camb) 2005; 13 (1): 29-41
14. Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004; 432 (7019): 917-21
15. Breustedt DA, Korndorfer IP, Redl B, et al. The 1.8-Å crystal structure of human tear lipocalin reveals an extended branched cavity with capacity for multiple ligands. J Biol Chem 2005; 280 (1): 484-93
16. Redl B. Human tear lipocalin. Biochim Biophys Acta 2000; 1482 (1-2): 241-8
17. Fluckinger M, Haas H, Merschak P, et al. Human tear lipocalin exhibits antimicrobial activity by scavenging microbial siderophores. Antimicrob Agents Chemother 2004; 48 (9): 3367-72
18. Gasymov OK, Abduragimov AR, Gasimov EO, et al. Tear lipocalin: potential for selective delivery of rifampin. Biochim Biophys Acta 2004; 1688 (2): 102-11
19. Hvidberg V, Jacobsen C, Strong RK, et al. The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett 2005; 579 (3): 773-7
20. Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005; 115 (3): 610-21
21. Wojnar P, Lechner M, Merschak P, et al. Molecular cloning of a novel lipocalin-1 interacting human cell membrane receptor using phage display. J Biol Chem 2001; 276 (23): 20206-12
22. Flower DR. Beyond the superfamily: the lipocalin receptors. Biochim Biophys Acta 2000; 1482 (1-2): 327-36
23. Rassart E, Bedirian A, Do Carmo S, et al. Apolipoprotein D. Biochim Biophys Acta 2000; 1482 (1-2): 185-98
24. Akerstrom B, Logdberg L, Berggard T, et al. α1-Microglobulin: a yellow-brown lipocalin. Biochim Biophys Acta 2000; 1482 (1-2): 172-84
25. Schlehuber S, Skerra A. Lipocalins in drug discovery: from natural ligand-binding proteins to 'anticalins'. Drug Discov Today 2005; 10 (1): 23-33
26. Paesen GC, Adams PL, Harlos K, et al. Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. Mol Cell 1999; 3 (5): 661-71
27. Kemp DH, Bourne A. Boophilus microplus: the effect of histamine on the attachment of cattle-tick larvae. Studies in vivo and in vitro. Parasitology 1980; 80 (3): 487-96
28. Couillin I, Maillet I, Vargaftig BB, et al. Arthropod-derived histamine-binding protein prevents murine allergic asthma. J Immunol 2004; 173 (5): 3281-6
29. Michaud GA, Salcius M, Zhou F, et al. Analyzing antibody specificity with whole proteome microarrays. Nat Biotechnol 2003; 21 (12): 1509-12
30. Walsh G. Biopharmaceutical benchmarks: 2003. Nat Biotechnol 2003; 21 (8): 865-70
31. Knappik A, Ge L, Honegger A, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 2000; 296 (1): 57-86
32. Soderlind E, Strandberg L, Jirholt P, et al. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat Biotechnol 2000; 18 (8): 852-6
33. Kay BK, Kasanov J, Yamabhai M. Screening phage-displayed combinatorial peptide libraries. Methods 2001; 24 (3): 240-6
34. Schlehuber S, Beste G, Skerra A. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. J Mol Biol 2000; 297 (5): 1105-20
35. Groves MA, Osbourn JK. Applications of ribosome display to antibody drug discovery. Expert Opin Biol Ther 2005; 5 (1): 125-35
36. Lipovsek D, Pluckthun A. In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods 2004; 290 (1-2): 51-67
37. Feldhaus MJ, Siegel RW, Opresko LK, et al. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol 2003; 21 (2): 163-70
38. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988; 48 (24 Pt 1): 7022-32
39. Skerra A. 'Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties. J Biotechnol 2001; 74 (4): 257-75
40. Schmidt FS, Skerra A. The bilin-binding protein of Pieris brassicae: cDNA sequence and regulation of expression reveal distinct features of this insect pigment protein. Eur J Biochem 1994; 219 (3): 855-63
41. Beste G, Schmidt FS, Stibora T, et al. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc Natl Acad Sci U S A 1999; 96 (5): 1898-903
42. Huber R, Schneider M, Mayr I, et al. Molecular structure of the bilin binding protein (BBP) from Pieris brassicae after refinement at 2.0 Å resolution. J Mol Biol 1987; 198 (3): 499-513
43. Voss EWJ. Fluorescein hapten: an immunological probe. Boca Raton (FL): CRC Press, 1984
44. McCreery T. Digoxigenin labeling. Mol Biotechnol 1997; 7 (2): 121-4
45. Hauptman PJ, Kelly RA. Digitalis. Circulation 1999; 99 (9): 1265-70
46. Mercader JV, Skerra A. Generation of anticalins with specificity for a nonsymmetric phthalic acid ester. Anal Biochem 2002; 308 (2): 269-77
47. Korndörfer IP, Beste G, Skerra A. Crystallographic analysis of an 'anticalin' with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region. Proteins 2003; 53 (1): 121-9
48. Korndörfer IP, Schlehuber S, Skerra A. Structural mechanism of specific ligand recognition by a lipocalin tailored for the complexation of digoxigenin. J Mol Biol 2003; 330 (2): 385-96
49. Jeffrey PD, Schildbach JF, Chang CY, et al. Structure and specificity of the anti-digoxin antibody 40-50. J Mol Biol 1995; 248 (2): 344-60
50. McMillin GA, Owen WE, Lambert TL, et al. Comparable effects of DIGIBIND and DigiFab in thirteen digoxin immunoassays. Clin Chem 2002; 48 (9): 1580-4
51. Ward SB, Sjostrom L, Ujhelyi MR. Comparison of the pharmacokinetics and in vivo bioaffinity of DigiTAb versus Digibind. Ther Drug Monit 2000; 22 (5): 599-607
52. Lechat P, Mudgett-Hunter M, Margolies MN, et al. Reversal of lethal digoxin toxicity in guinea pigs using monoclonal antibodies and Fab fragments. J Pharmacol Exp Ther 1984; 229 (1): 210-3
53. Kelly R, Peim A, Walz A, et al. Reversal of digoxin cardiac toxicity by an anticalin (digical II) in the anaesthetized guinea pig [online]. Available from URL: http:// www.physoc.org/publications/proceedings/archive/article.asp? id=560ppc7 [Accessed 2005 Aug 25]
54. Skerra A, Schlehuber S. Muteins of human neutrophil gelatinase-associated lipocalin and related proteins [patent application]. 2003; WO 03/029463 A2
55. Vogt M, Skerra A. Construction of an artificial receptor protein ('anticalin') based on the human apolipoprotein D. Chem Bio Chem 2004; 5 (2): 191-9
56. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271 (5256): 1734-6
57. Davis SJ, Ikemizu S, Evans EJ, et al. The nature of molecular recognition by T cells. Nat Immunol 2003; 4 (3): 217-24
58. Madrenas J, Chau LA, Teft WA, et al. Conversion of CTLA-4 from inhibitor to activator of T cells with a bispecific tandem single-chain Fv ligand. J Immunol 2004; 172 (10): 5948-56
59. Keler T, Halk E, Vitale L, et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol 2003; 171 (11): 6251-9
60. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100 (14): 8372-7
61. Camacho LH, Ribas A, Glaspy JA, et al. Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies [online]. Available from URL: http://meeting.jco.org/cgi/ content/ abstract/22/14_suppl/2505 [Accessed 2005 Aug 25]
62. Lane P. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86. Ann N Y Acad Sci 1997; 815: 392-400
63. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1 (2): 118-29
64. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004; 55: 477-503
65. Toi M, Takada M, Bando H, et al. Current status of antibody therapy for breast cancer. Breast Cancer 2004; 11 (1): 10-4
66. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2 (10): 750-63
67. Ghetie V, Ward ES. Transcytosis and catabolism of antibody. Immunol Res 2002; 25 (2): 97-113
68. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005; 19 (2): 176-82
69. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003; 98 (10): 2095-104
70. Pastan I. Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol Immunother 2003; 52 (5): 338-41
71. ClinicalTrials.gov. US National Institutes of Health [online]. Available from URL: http://clinicaltrials.gov [Accessed 2005 Aug 9]
72. Schlehuber S, Skerra A. Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold. Biol Chem 2001; 382 (9): 1335-42
73. Syrigos KN, Epenetos AA. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Anticancer Res 1999; 19 (1A): 605-13
74. Wilde MI, Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 1996; 51 (5): 865-94
75. Reichert J, Pavolu A. Monoclonal antibodies market. Nat Rev Drug Discov 2004; 3 (5): 383-4
76. Nygren PA, Skerra A. Binding proteins from alternative scaffolds. J Immunol Methods 2004; 290 (1-2): 3-28
77. Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 2002; 16 (2): 111-48
78. Bain B, Brazil M. Adalimumab. Nat Rev Drug Discov 2003; 2 (9): 693-4
79. Bonnefoy A, Vermylen J, Hoylaerts MF. Inhibition of von Willebrand factor-GPIb/IX/V interactions as a strategy to prevent arterial thrombosis. Expert Rev Cardiovasc Ther 2003; 1 (2): 257-69
80. Cauwenberghs N, Meiring M, Vauterin S, et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol 2000; 20 (5): 1347-53
81. Goodman DS. Plasma retinol-binding protein. In: Sporn M, Roberts AB, Goodman DS, editors. The retinoids. New York: Academic Press, 1984: 41-87
82. Axelsson L, Bergenfeldt M, Ohlsson K. Studies of the release and turnover of a human neutrophil lipocalin. Scand J Clin Lab Invest 1995; 55 (7): 577-88
83. Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004; 15 (12): 3073-82
84. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2 (3): 214-21
85. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002; 24 (11): 1720-40
86. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003; 109 (1): 1-11